- ≥99% HPLC purity
- Lot-matched certificate of analysis
- Ships next business day, tracked
Tadalafil — Research Liquid
PDE5 inhibitor reference listing — 30 mL at 30 mg/mL, long half-life profile
- FormClear solution in an amber bottle with a graduated dispenser
- Mol. weight389.40 g/mol
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme that hydrolyses cyclic guanosine monophosphate in vascular smooth muscle. It is a small heterocyclic molecule — a beta-carboline-derived tetracyclic diketopiperazine, molecular formula C22H19N3O4 and molecular weight about 389.4 g/mol — and is not a peptide. It is best known in the regulatory record as the active ingredient of Cialis and Adcirca.
As a matter of public regulatory fact, tadalafil holds approvals for erectile dysfunction, for the signs and symptoms of benign prostatic hyperplasia, and — under a separate brand and strength — for pulmonary arterial hypertension. Its long plasma half-life relative to other PDE5 inhibitors is the pharmacological property most often discussed in the literature. The 30 mL solution at 30 mg/mL listed here is presented for reference and analytical purposes only.
Specifications
Identity
- CAS number
- 171596-29-5
- Molecular formula
- C22H19N3O4
- Molecular weight
- 389.40 g/mol
Supply & purity
- Form
- Clear solution in an amber bottle with a graduated dispenser
- Solubility
- Practically insoluble in water; soluble in DMSO and in organic solvents used for analytical work
Additional detail
- Listing type
- Prescription-only reference item; released only against valid authorisation
- Listed presentation
- 30 mL at 30 mg/mL
- Compound class
- Selective phosphodiesterase type 5 (PDE5) inhibitor
- Chemical description
- Tetracyclic beta-carboline-derived diketopiperazine with a methylenedioxyphenyl substituent
- Reference brand names
- Cialis (ED and BPH indications); Adcirca (pulmonary arterial hypertension)
- Mechanism
- Blocks cGMP hydrolysis by PDE5, prolonging nitric-oxide-driven smooth muscle relaxation
- Approved indications (regulatory fact)
- Erectile dysfunction; signs and symptoms of benign prostatic hyperplasia; pulmonary arterial hypertension
- Pharmacology note
- Long elimination half-life relative to sildenafil and vardenafil; PDE5-selective with modest PDE11 affinity
- Storage
- Room temperature, upright, tightly closed and protected from light
Questions about Tadalafil — Research Liquid
Is this available without a prescription?
No. Tadalafil is a prescription-only medicine in the United States and comparable jurisdictions. This listing exists as an institutional reference entry and material is released only against valid authorisation from a licensed practitioner or a credentialed research institution.
What is tadalafil approved for?
As a matter of public regulatory record, it is approved for erectile dysfunction, for the signs and symptoms of benign prostatic hyperplasia, and — under a separate brand and strength — for pulmonary arterial hypertension. Stating those approvals is a factual description, not a recommendation.
Is a certificate of analysis available?
Yes. Identity and purity are documented on a lot-matched certificate of analysis, available on request when you quote the lot number. For reference and analytical work, lot-level documentation is the point of the listing.
Related
